1. Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T., Bingham, C.O. 3rd., Birnbaum, N.S., Burmester, G.R., Bykerk, V.P., Cohen, M.D., Combe, B., Costenbader, K.H., Dougados, M., Emery, P., Ferraccioli, G., et al. (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum., 62, 2569-2581.
2. Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., Healey, L.A., Kaplan, S.R., Liang, M.H., Luthra, H.S., Medsger, T.A., Mitchell, D.M., Neustadt, D.H., Pinals, R.S., Schaller, J.G., et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum., 31, 315-324.
3. Day, F.L., Karnon, J. & Rischin, D. (2011a) Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J. Clin. Oncol., 29, 3270-3277.
4. Day, F.L., Link, E., Thursky, K. & Rischin, D. (2011b) Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J. Oncol. Pract., 7, 141-147.
5. Harigai, M., Mochida, S., Mimura, T., Koike, T. & Miyasaka, N. (2014) A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. Mod. Rheumatol., 24, 1-7.